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Abstract 
Angiogenesis is a key pathological feature of experimental and human steatohepatitis, a common 
chronic liver disease that is associated with obesity. We demonstrated that hepatocytes generated a 
type of membrane-bound vesicle, microparticles, in response to conditions that mimicked the lipid 
accumulation that occurs in the liver in some forms of steatohepatitis and that these microparticles 
promoted angiogenesis. When applied to an endothelial cell line, medium conditioned by murine 
hepatocytes or a human hepatocyte cell line exposed to saturated free fatty acids induced migration 
and tube formation, two processes required for angiogenesis. Medium from hepatocytes in which 
caspase 3 was inhibited or medium in which the microparticles were removed by ultracentrifugation 
lacked proangiogenic activity. Isolated hepatocyte-derived microparticles induced migration and 
tube formation of an endothelial cell line in vitro and angiogenesis in mice, processes that depended 
on internalization of microparticles. Microparticle internalization required the interaction of the 
ectoenzyme Vanin-1 (VNN1), an abundant surface protein on the microparticles, with lipid raft 
domains of endothelial cells. Large quantities of hepatocyte-derived microparticles were detected in 
the blood of mice with diet-induced steatohepatitis, and microparticle quantity correlated with 
disease severity. Genetic ablation of caspase 3 or RNA interference directed against VNN1 
protected mice from steatohepatitis-induced pathological angiogenesis in the liver and resulted in a 
loss of the proangiogenic effects of microparticles. Our data identify hepatocyte-derived 
microparticles as critical signals that contribute to angiogenesis and liver damage in steatohepatitis 
and suggest a therapeutic target for this condition. 
Introduction 
Nonalcoholic fatty liver disease (NAFLD) is a common form of chronic liver disease that affects 
both adults and children and is associated with obesity and insulin resistance (1, 2). One in three 
adults and 1 in 10 children or adolescents in the United States have hepatic steatosis, a stage within 
the spectrum of NAFLD that is characterized by triglyceride accumulation in liver cells and usually 
follows a benign nonprogressive clinical course (3). Nonalcoholic steatohepatitis (NASH) is defined 
as lipid accumulation with evidence of cellular damage, inflammation, neovascularization, and 
different degrees of scarring or fibrosis (4). NASH is a serious condition because about 25% of 
these patients can progress to cirrhosis and related complications, including portal hypertension, 
liver failure, and hepatocellular carcinoma (5, 6). Growing evidence suggests that angiogenesis 
plays a central role in the progression to NASH, particularly the development of fibrosis (7). 
Marked hepatic neovascularization occurs in patients with NASH, as well as in experimental 
models of the disease, which parallel the extent of fibrosis present (8–11). The mechanisms leading 
to angiogenesis in NASH as well as various other chronic liver conditions remain incompletely 
understood. Increased abundance and release of proangiogenic factors such as vascular endothelial 
growth factor (VEGF) by activated Kupffer cells, the resident liver macrophages, have been 
implicated, likely as a result of local hypoxia (7). Moreover, the degree of angiogenesis in the liver 
of NASH patients correlates with the activation of caspase 3 in hepatocytes (12). However, the 
molecular and signaling mechanisms linking lipid accumulation within hepatocytes to angiogenesis 
and a potential link between lipotoxicity and angiogenesis remain largely unknown. This leads us to 
hypothesize that lipid-overloaded hepatocytes may release proangiogenic signals that regulate 
endothelial cell migration and angiogenesis. Here, we present evidence that hepatocytes, after 
exposure to excessive amounts of saturated, but not unsaturated, free fatty acids (FFAs), secrete 
proangiogenic signals. Through several lines of evidence, we further identified hepatocyte-derived 
microparticles as the putative proangiogenic factor both in vitro and in vivo in a process involving 
caspase 3 activation in hepatocytes and Vanin-1 (VNN1)–dependent internalization of 
microparticles into endothelial cells. These findings uncover a mechanism that links hepatocyte 
lipotoxicity to angiogenesis and identifies a potential therapeutic target to inhibit angiogenesis and 
disease progression. 
Results 
Lipid-loaded hepatocytes release factors that induce endothelial cell migration and 
tube formation 
Lipid accumulation in hepatocytes is a critical event in NASH development and is thought to be 
mainly a result of increased uptake of FFAs from the circulation (13). We and others have 
demonstrated that overloading hepatocytes with saturated FFAs such as palmitic acid, rather than 
monounsaturated or polyunsaturated FFAs, results in lipotoxicity (14–16). To determine whether 
accumulation of lipotoxic FFAs in hepatocytes results in the release of factor (or factors) that 
induces angiogenesis, we initially collected cell-free supernatants from media conditioned by 
HepG2 cells, a well-differentiated human and hepatoma cell line, or primary rat hepatocytes 
exposed to lipotoxic FFAs such as palmitic and stearic acid, as well as to nonlipotoxic FFAs (such 
as oleic acid) or controls (fig. S1). Cell-free supernatants from hepatocytes treated with palmitic or 
stearic acid, but not those from hepatocytes treated with oleic acid, induced an increase in tube 
formation, chemotaxis, and nonoriented migration in human umbilical vascular endothelial cells 
(HUVECs) to an extent similar to that induced by proangiogenic doses of the positive control 
VEGF-A (Fig. 1, A to C). These results suggest that overloading hepatocytes with lipotoxic FFAs 
results in the formation and release of proangiogenic factors. 
 
 
Fig. 1 Lipid-loaded hepatocytes release factors that induce endothelial cell migration and 
angiogenesis.  
(A) Quantification of tube formation after exposure of HUVECs to palmitic acid–treated HepG2 
cell supernatant (supernatant) or vesicle-free supernatant obtained by ultracentrifugation. *P < 0.05; 
**P < 0.01; ***P < 0.001, Kruskal-Wallis with Bonferroni correction. (B) Quantification of 
chemotaxis in Boyden chambers showing the number of migrated HUVECs after exposure to 
palmitic acid–treated HepG2 cell supernatant (supernatant) or vesicle-free supernatant. *P < 0.05; 
**P < 0.01; ***P < 0.001, analysis of variance (ANOVA) with Bonferroni correction. (C) 
Quantification of wound healing assay (to measure nonoriented migration) of HUVECs, monitored 
by confocal time-lapse microscopy for up to 48 hours. Quantification was reported as cell-covered 
area (%). VEGF was used as a positive control, and serum-free medium as a negative control. *P < 
0.05; **P < 0.01; ***P < 0.001, Kruskal-Wallis with Bonferroni correction. Values represent 
means ± SD from three independent experiments. 
The proangiogenic effects of lipid-loaded hepatocytes are mediated by the release of 
membrane vesicles 
We then sought to determine the nature of the proangiogenic factor (or factors) released by stressed 
hepatocytes. During initial studies focused on physical and biochemical characterization of the 
proangiogenic factor (or factors), we removed cell vesicles from media conditioned by palmitic 
acid–treated hepatocytes by ultracentrifugation. We found that vesicle-free supernatants did not 
promote endothelial tube formation and migration in vitro (Fig. 1, A to C). These findings 
suggested that the proangiogenic activity was present in the membranous precipitate and led us to 
further characterize the membrane vesicles released by hepatocytes during lipotoxicity. We next 
performed dynamic light scattering analysis, transmission electron microscopy (TEM), and 
fluorescence-activated cell sorting (FACS) analysis and identified microparticles as the main 
membrane vesicle population released by hepatocytes during exposure to saturated FFAs (Fig. 2, A 
to C). The vesicles released in the supernatant had a diameter ranging between 100 and 1000 nm 
(mean, 220 nm) and a morphology similar to that of microparticles (Fig. 2, B and C) (17, 18). 
Moreover, FACS analysis showed that there were higher numbers of annexin V–positive 
microparticles in the supernatants of palmitic acid–treated cells than in those of control cells (Fig. 2, 
D and E). The release of microparticles was linked to lipotoxicity because incubation of hepatocytes 
with a nonlipotoxic FFA failed to induce an increase in microparticle formation (Fig. 2, D and E), 
whereas coincubation of cells with both a lipotoxic FFA (palmitic acid) and a nonlipotoxic FFA 
(oleic acid) abrogated the release of microparticles (fig. S2). Because microparticle generation by 
other cell types such as platelets requires caspase 3 (19, 20), we next assessed whether suppression 
of caspase 3 activity would abolish or reduce microparticle formation and release triggered by 
palmitic acid treatment. Coincubation of palmitic acid–treated hepatocytes with a selective caspase 
3 inhibitor reduced the formation and release of microparticles (Fig. 2, F and G). We next 
characterized the composition of hepatocyte-derived microparticles using a proteomic approach by 
liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis. Table 1 lists the most 
abundant proteins identified in hepatocyte-derived microparticles, and table S1 lists all the proteins 
identified in three independent experiments. Hepatocyte-derived microparticles carry (in order of 
abundance) cytosolic, extracellular, plasma membrane, and nuclear proteins (fig. S3). These data 
demonstrate that during lipotoxicity, microparticles with a specific composition are released from 
hepatocytes in a process dependent on caspase 3 activation and that these hepatocyte-derived 
microparticles may be critical mediators of the angiogenic effects exerted by the supernatants of 
lipid-loaded hepatocytes. 
 
Fig. 2 Microparticles are the main membrane vesicle population released by hepatocytes during 
exposure to lipotoxic fatty acids.  
(A) Flow cytometry analysis was performed to quantify annexin V fluorescein isothiocyanate 
(FITC)–positive microparticles (MPs; green peak) released by HepG2 after exposure to palmitic 
acid. The presence of hepatocyte-derived microparticles was measured in microparticle-free 
supernatant (brown peak) and 1% bovine serum albumin (BSA) (black peak), which were used as 
negative controls. The analysis is representative of three independent experiments. (B) Dynamic 
light scattering analysis of the size (diameter) of hepatocyte-derived microparticles released after 
exposure to palmitic acid. The analysis is representative of three independent experiments. (C) 
TEM micrographs of hepatocyte-derived microparticles released after palmitic acid treatment. Scale 
bars, 500 and 100 nm. Images are representative of three independent experiments. (D) Graph 
showing flow cytometric analysis to quantify annexin V–positive microparticles released by HepG2 
treated with palmitic acid (PA), stearic acid (SA), oleic acid (OA), or BSA (control vehicle for 
FFAs). (E) Graph showing flow cytometric analysis to quantify annexin V–positive microparticles 
released by primary rat hepatocytes treated with palmitic acid, oleic acid, or BSA (control vehicle 
for FFAs). (D and E) *P < 0.05; **P < 0.01; ***P < 0.001, Kruskal-Wallis with Bonferroni 
correction. (F) Graph showing flow cytometric analysis of the number of annexin V–positive 
microparticles after coincubation of HepG2 with a caspase 3 inhibitor. (G) Graph of flow 
cytometric analysis of the number of annexin V–positive microparticles after coincubation of 
primary rat hepatocytes with a caspase 3 inhibitor. (F and G) *P < 0.05; **P < 0.01; ***P < 0.001, 
Mann-Whitney test. (D to G) Values represent means ± SD from three independent experiments. 
Table 1 List of the most abundant proteins in hepatocyte-derived microparticles based on LC-
MS/MS analysis.  
Pure hepatocyte-derived microparticles were isolated and processed for proteomics analysis. Some 
of the most abundant proteins are listed in the table with the corresponding UniProt accession code, 
sequence of coverage (%), number of peptides, and molecular mass based on the Gene Ontology 
Consortium. Proteomics data are representative of three independent experiments. Identification of 
the highest expressed hepatocyte-derived microparticle proteins based on LC-MS/MS data. 
Table 1 List of the most abundant proteins in hepatocyte-derived microparticles based on LC-
MS/MS analysis.  
Pure hepatocyte-derived microparticles were isolated and processed for proteomics analysis. Some 
of the most abundant proteins are listed in the table with the corresponding UniProt accession code, 
sequence of coverage (%), number of peptides, and molecular mass based on the Gene Ontology 
Consortium. Proteomics data are representative of three independent experiments. Identification of 
the highest expressed hepatocyte-derived microparticle proteins based on LC-MS/MS data. 






Maltase-glucoamylase MGA_HUMAN       17.99        20 196.9 
Ceruloplasmin precursor CERU_HUMAN       35.96        38 122.2 
Amine oxidase, copper 
containing 3 
AOC3_HUMAN       15.07        10 84.6 
Apolipoprotein E precursor APOE_HUMAN        30.6          6 36.1 
Vitamin D–binding protein 
precursor 
VTDB_HUMAN       12.66          7 52.9 
Isocitrate dehydrogenase 1, 
soluble 
IDHC_HUMAN       12.56          4 46.6 
Fumarylacetoacetate 
hydrolase 
FAAA_HUMAN       18.62          5 46.3 
Vanin-1 VNN1_HUMAN       13.06          3 57 
Transforming growth factor 
β–induced 
BGH3_HUMAN       10.25          3 74.6 
Hepatocyte-derived microparticles are proangiogenic and induce endothelial cell 
migration and tube formation in vitro and angiogenesis in vivo in a process 
requiring VNN1-dependent internalization 
We further explored the role of hepatocyte-derived microparticles in key events involved in 
angiogenesis. Isolated hepatocyte-derived microparticles from either HepG2 cells (Fig. 3, A to C) or 
primary rat hepatocytes (fig. S4, A to D) treated with palmitic acid resulted in increased migration 
and tube formation activity in HUVECs in vitro in a dose-dependent manner (fig. S5, A and B). 
Moreover, in the tube formation assays, we detected microparticles inside the tubular structures, 
suggesting that microparticles were internalized by HUVECs (fig. S6). Next, to elucidate whether 
hepatocyte-derived microparticles could contribute to angiogenesis in vivo, we intradermally 
injected hepatocyte-derived microparticles mixed with Matrigel into athymic BALB/c nude mice. 
Hepatocyte-derived microparticles induced angiogenesis in the Matrigel plugs to an extent similar 
to that induced by injecting VEGF mixed with Matrigel (Fig. 3D). Our proteomic analysis of 
microparticles led us to focus on VNN1 as a functional candidate for microparticle-induced 
proangiogenic responses in endothelial cells. VNN1 is an ectoenzyme (an enzyme localized to the 
cell surface) that contains a glycosylphosphatidylinositol (GPI)–anchored cleavage site on residue 
491. VNN1 is found primarily in the liver, kidney epithelia, and intestine (21) and has been linked 
to promotion of cell adherence and migration (22). Western blot analysis confirmed that VNN1 was 
present in hepatocytes and in microparticles from palmitic acid–treated cells, but not in those from 
oleic acid–treated cells (Fig. 4A), and imaging analysis demonstrated that fluorescently labeled 
microparticles were internalized into HUVECs within 6 hours of incubation (Fig. 4B). Because 
GPI-anchored proteins are often associated with lipid raft domains in the plasma membrane, we 
investigated whether VNN1 promoted the internalization of microparticles through lipid rafts (23, 
24). Caveolae are flask-like invaginations of the plasma membrane that are enriched in cholesterol, 
glycosphingolipids, and the structural proteins caveolins and are a subset of lipid rafts; they can 
participate in the uptake of extracellular vesicles (25–27). To determine whether the internalization 
of microparticles is mediated by the interaction of VNN1 with lipid raft domains of the endothelial 
cells, we incubated live HUVECs with cholera toxin B (CTB)–horseradish peroxidase (HRP) 
conjugate to label lipid rafts (28), then with VNN1-gold–labeled microparticles. Immunogold 
electron microscopy showed that VNN1-positive microparticles colocalized with lipid rafts and 
suggested that microparticles were taken up and trafficked in HUVECs through lipid rafts (Fig. 4C). 
Cholesterol depletion through combination treatment of cells with methyl-β-cyclodextrin (MβCD), 
which disrupts lipid rafts and caveolae (29), and a neutralizing antibody to caveolin-1 resulted in 
reduced internalization of microparticles into endothelial cells (Fig. 4D). Intracellular signal 
transduction through lipid raft and GPI-anchored proteins may require activation of small guanosine 
triphosphatases, such as RhoA and cdc42 (30–32). We found that the RhoA-associated kinase 
(ROCK) inhibitor Y27632 or knockdown of cdc42 in endothelial cells resulted in a significant 
decrease in tube formation and chemotaxis (Fig. 4, E and F). To further assess the role of VNN1 in 
the internalization of microparticles, we treated HepG2 cells with small interfering RNA (siRNA) 
for VNN1 or with control siRNA before incubating the cells with palmitic acid. VNN1 siRNA, but 
not control siRNA, reduced VNN1 abundance in both HepG2 cells and the microparticles released 
after exposure to palmitic acid (Fig. 5, A and B), although knockdown of VNN1 did not affect the 
number of microparticles released after exposure to palmitic acid (Fig. 5C). Furthermore, 
knockdown of VNN1 significantly reduced the internalization of microparticles by endothelial cells 
(Fig. 5, D to F) and the ability of microparticles to promote endothelial cell migration and tube 
formation (Fig. 5, G and H, and fig. S7, A and B). Blocking VNN1 on the surface of microparticles 
with a neutralizing VNN1 antibody resulted in effects on microparticle internalization and HUVEC 
migration and tube formation similar to those observed with VNN1 siRNA (fig. S8, A to E). VNN1 
has pantetheinase activity, which results in reduction of intracellular glutathione in the target cell; 
however, application of VNN1-positive microparticles to HUVECs did not significantly alter 
glutathione activity (fig. S8F). 
 
 
Fig. 3 Endothelial cell tube formation and migration depend on microparticles released from fat-
laden HepG2 cells.  
(A) Representative micrographs and corresponding quantification of tube formation of HUVECs 
after exposure to microparticle (MP)–free supernatant or HepG2-derived microparticles. Scale bar, 
50 μm. (B) Representative micrographs and corresponding quantification of chemotaxis in Boyden 
chamber assays of HUVECs exposed to HepG2-derived microparticles, microparticle-free 
supernatant, and controls. Scale bar, 50 μm. (C) Representative micrographs and corresponding 
quantification of wound healing assay of HUVECs. Scale bar, 50 μm. (D) Representative Masson’s 
trichrome micrographs of angiogenesis and migration assay in vivo and corresponding 
quantification of the number of endothelial cells (ECs) (dark red) that migrated into the plug 
removed from athymic BALB/c nude mice (n = 5 mice per group) that received a subcutaneous 
injection of Matrigel in the presence or absence (control) of VEGF, microparticle-free supernatant, 
and HepG2-derived microparticles. Scale bar, 50 μm. VEGF was used as a positive control, and 
serum-free medium as a negative control (Control). Values in (B) and (C) represent means ± SD 
from three independent experiments.*P < 0.05; **P < 0.01; ***P < 0.001, Kruskal-Wallis with 
Bonferroni correction. 
  
Fig. 4 Hepatocyte-derived microparticles express VNN1 and are internalized into the endothelial 
cells.  
(A) Western blotting analysis of VNN1 in HepG2 and HepG2-derived microparticles (MPs) 
released after exposure to BSA (FFA control vehicle) and saturated [palmitic acid (PA)] or 
unsaturated [oleic acid (OA)] FFAs. Controls refer to untreated HepG2 or microparticle-free 
supernatant. (B) Internalization of HepG2-derived PKH26-positive microparticles (red) into 
HUVECs (F-actin fibers, green; nuclei, blue) assessed by indirect immunofluorescence after 
incubation with microparticles. Scale bar, 50 μm. (C) TEM micrographs of HUVECs incubated 
with CTB-HRP conjugate and VNN1 antibody–gold conjugate–labeled microparticles. CTB-HRP 
conjugate labeling is shown on the plasma membrane of HUVECs (arrows, top panel), and VNN1 
antibody–gold conjugate is shown on microparticles internalized in the HUVECs (arrows, bottom 
panel). Scale bars, 50 nm. (D) Representative micrographs and corresponding quantification of 
internalization of microparticles assessed by immunofluorescence in HUVECs pretreated with 
MβCD or neutralizing antibody to caveolin-1 (cav-1 nAb). Micrographs show PKH26-positive 
microparticles (red), F-actin fibers of HUVECs (green), and nuclei [4′,6-diamidino-2-phenylindole 
(DAPI), blue]. Microparticle-free supernatant (microparticle-free sup.) was used as a negative 
control. Data in (A) to (D) are representative of three independent experiments. Scale bar, 50 μm. 
(E and F) Quantification of tube formation (E) and chemotaxis assay in Boyden chambers (F) of 
HUVECs pretreated with the ROCK inhibitor Y27632, cdc42 siRNA, or control siRNA (Ctrl 
siRNA). Values in (E) and (F) represent means ± SD from three independent experiments. *P < 
0.05; **P < 0.01; ***P < 0.001, Kruskal-Wallis (E) and ANOVA (F) with Bonferroni correction. 
  
Fig. 5 Knockdown of VNN1 reduces microparticle internalization and proangiogenic effects on 
endothelial cells.  
(A) Western blotting analysis of VNN1 in HepG2-derived microparticles and HepG2 cells treated 
with VNN1 siRNA or control siRNA (Ctrl siRNA) and exposed to palmitic acid (PA). Western 
blots are representative of three independent experiments. (B) Flow cytometry analysis of VNN1-
positive microparticles (MPs) isolated from HepG2 cells exposed to palmitic acid in the presence or 
absence of VNN1 siRNA. *P < 0.05; **P < 0.01; ***P < 0.001, Mann-Whitney test. (C) Flow 
cytometry analysis of annexin V–positive microparticles released from HepG2 cells treated with 
VNN1 siRNA or control siRNA and exposed to palmitic acid. (D and E) Flow cytometry analysis 
(D) and corresponding quantification (E) of the number of calcein/FITC-positive HUVECs exposed 
to microparticles isolated from HepG2 cells treated with VNN1 siRNA or control siRNA and 
exposed to palmitic acid. *P < 0.05; **P < 0.01; ***P < 0.001, Kruskal-Wallis with Bonferroni 
correction. (F) Internalization of PKH26-positive HepG2-derived microparticles or microparticles 
lacking VNN1 (VNN1
−/−
) (red) into HUVECs (green), assessed by indirect immunofluorescence. 
Images are representative of three independent experiments. (G and H) Quantification of tube 
formation (G) and chemotaxis using Boyden chambers (H) of HUVECs incubated with 
microparticles isolated from HepG2 cells treated with VNN1 siRNA or control siRNA and exposed 
to palmitic acid. VEGF was used as a positive control, and serum-free medium as a negative 
control. Values in (B), (C), (E), (G), and (H) represent means ± SD from three independent 
experiments. *P < 0.05; **P < 0.01; ***P < 0.001, Kruskal-Wallis (G) and ANOVA (H) with 
Bonferroni correction. 
VNN1 can promote the proliferation of vascular smooth muscle cells partly through the 
transcription factor PPARγ (peroxisome proliferator–activated receptor γ) (33). However, we found 
that the proangiogenic effects of microparticles on HUVECs did not involve modulation of PPARγ 
expression and were not associated with an increase in cell proliferation (fig. S9, A and B). This is 
consistent with a previous report demonstrating that cells organize themselves into tube-like 
structures mainly by changing their shape and establishing contacts with neighboring cells without 
proliferating to a substantial extent (34). In addition, the lipotoxicity-dependent increase in VNN1 
abundance has been reported to depend on PPAR factors (35). In our study, the exposure of HepG2 
cells to saturated and unsaturated FFAs increased the mRNA expression of PPARα and VNN1 but 
not that of PPARγ (fig. S10, A to C). However, silencing of PPARα did not affect the mRNA 
expression of VNN1 in HepG2 cells in response to palmitic acid treatment (fig. S10, D and E), 
suggesting that the response was independent of PPARα. These results show that microparticle-
mediated angiogenesis occurs through VNN1-dependent internalization into target cells. 
Circulating microparticles are released during experimental NASH, are positive for 
VNN1, and have proangiogenic effects 
We used a common dietary murine model of NASH to determine the potential role of hepatocyte-
derived microparticles in hepatic angiogenesis during steatohepatitis development in vivo. C57BL/6 
mice were placed on a methionine- and choline-deficient (MCD) diet, which results in steatosis 
associated with substantial inflammation and progressive fibrosis that is pathologically similar to 
severe steatohepatitis in humans (36, 37). Unlike mice receiving the control methionine- and 
choline-supplemented (MCS) diet, mice on the MCD diet showed an increase in circulating annexin 
V–positive microparticles, an increase that was partially reduced in caspase 3 knockout mice (Fig. 
6A), suggesting that caspase 3 activity may be critical in the production and/or release of circulating 
microparticles during experimental NASH. Furthermore, VNN1 was present on the circulating 
microparticles isolated from wild-type MCD-fed mice but not on those isolated from mice that 
received the control diet or from caspase 3 knockout mice (Fig. 6B). In addition, MCD-fed mice 
had more annexin V–positive microparticles than mice fed a high-fat, high-carbohydrate diet 
(HF/HCarb), which results in hepatic steatosis in the absence of liver injury or inflammation (38, 
39), indicating that the circulating numbers of microparticles correlated with the severity of liver 
pathology (fig. S11, A to C). Light scattering and electron microscopy analysis demonstrated that 
the size range and morphology of microparticles in the MCD-treated animals were similar to those 
found in supernatants of palmitic acid–treated hepatocytes (Fig. 6, C and D). Finally, electron 
microscopy showed the presence of abundant vesicles with a morphology characteristic of 
microparticles in liver sections from MCD-treated but not in those from MCS-treated mice. These 
vesicles were present predominantly in perisinusoidal areas or space of Disse, which is located 
between hepatocytes and a sinusoid, and could be easily distinguished from hepatocyte microvilli 
that typically extend into this space (Fig. 6C). To establish whether the circulating microparticles 
isolated from MCD- or MCS-fed mice originated from hepatocytes, we measured the abundance of 
the hepatocyte-specific microRNA miR-122 (40, 41) and found that miR-122 abundance was higher 
in circulating microparticles isolated from MCD-fed mice than in those isolated from mice on the 
control diet (Fig. 6E). Next, we wanted to determine whether circulating VNN1-positive 
microparticles in MCD-treated mice had similar biological effects on endothelial cells as those 
derived from hepatocytes in vitro. We treated HUVECs with microparticle-free plasma or 
microparticles isolated from the blood of C57BL/6 mice on MCD, HF/HCarb, or normal chow 
diets, and found that blood microparticles from MCD-treated mice induced tube formation and 
oriented migration in endothelial cells to a similar extent to those induced by microparticles from 
palmitic acid–treated hepatocytes (fig. S12, A and B). To evaluate the role of VNN1 in circulating 
microparticles, we treated C57BL/6 mice on the MCD with VNN1 siRNA or control siRNA. 
Hepatic VNN1 was reduced up to 90% in mice treated with VNN1 siRNA compared to phosphate-
buffered saline (PBS)–treated mice (Fig. 7A), whereas the abundance of mRNA for VNN1 was 
unchanged in the kidney or intestine (fig. S13, A to C). Western blotting analysis of circulating 
microparticles confirmed that VNN1 was present in microparticles isolated from MCD-fed mice, 
but not in those isolated from MCS-fed mice, and that circulating microparticles lacking VNN1 
were present only after treatment with VNN1 siRNA, but not after mock treatment or treatment 
with control siRNA (Fig. 7B). Knockdown of VNN1 did not influence the number of circulating 
microparticles (Fig. 7C). HUVECs treated with circulating microparticles lacking VNN1 showed 
reduced tube formation and chemotaxis compared to cells treated with microparticles from either 
mock or control siRNA–treated mice (Fig. 7, D to G). Additionally, mice on the MCD diet and 
treated with VNN1 siRNA showed reduced abundance not only of the mRNAs encoding the 
angiogenic markers VEGF-A and vascular endothelial cadherin (VE-cadherin) (42) but also of the 
mRNA encoding CD31, a histological marker for endothelial cells, compared to the mice treated 
with control siRNA or PBS (mock) (fig. S14, A to C). 
 
 
Fig. 6 Microparticles are released into circulation in a diet-induced NASH murine model.  
(A) Flow cytometry analysis of circulating annexin V–positive microparticles (MPs) isolated from 
wild-type (WT; control) mice (n = 5) and caspase 3 knockout (Casp3
−/−
) mice (n = 5) fed with the 
MCD to induce NASH or the control diet (MCS). *P < 0.05; **P < 0.01; ***P < 0.001, Kruskal-
Wallis with Bonferroni correction. (B) Western blotting analysis of VNN1 abundance in circulating 
microparticles isolated from MCS-fed (n = 3) or MCD-fed (n = 5) WT and caspase 3 knockout 
mice. The lanes were run on the same gel but were noncontiguous. (C) Representative TEM 
micrographs of circulating microparticles isolated from WT MCD-fed mice (left) and of 
microparticles localized in liver specimens from MCD-fed mice (right) (n = 5 mice). DS, space of 
Disse; m, microvilli; H, hepatocytes; Ld, lipid droplet. (D) Dynamic light scattering analysis of the 
size (diameter) of circulating purified microparticles from MCD-fed mice (n = 5). (E) Quantitative 
PCR of miR-122 abundance in the circulating microparticles isolated from MCD- or MCS-fed mice 
(n = 5 mice per group). Mean values were normalized to U6 small nuclear RNA (snRNA). Values 
represent means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001, Mann-Whitney test. 
  
Fig. 7 In vivo knockdown of hepatic VNN1 resulted in decreased microparticle internalization and 
proangiogenic effects on endothelial cells.  
(A) Quantitative PCR of hepatic VNN1 mRNA expression in mice (n = 8 mice per group) placed on 
MCD or control diet (MCS) for 6 weeks. MCD-fed mice received VNN1 siRNA, control siRNA 
(Ctrl siRNA), or PBS (mock) as vehicle. Mean values were normalized to 18S gene. (B) Western 
blotting analysis of VNN1 abundance in circulating microparticles (MPs) isolated from MCS-fed 
mice (control diet) and MCD-fed mice treated with VNN1 siRNA, control siRNA, or PBS (mock) 
(n = 3 mice per group). Each lane represents microparticles isolated from an individual mouse. (C) 
Flow cytometry analysis of annexin V–positive circulating microparticles collected from MCS-fed 
mice (control diet) and MCD-fed mice treated with VNN1 siRNA, control siRNA, or PBS (mock) 
(n = 8 mice per group). (D and E) Representative micrographs (D) and corresponding quantification 
(E) of internalization of microparticles isolated from MCS-fed mice (control diet) and MCD-fed 
mice treated with VNN1 siRNA, control siRNA, or PBS (mock) (n = 5 mice per group). 
Micrographs show PKH26-positive microparticles (red), F-actin fibers of HUVECs (green), and 
nuclei (DAPI, blue). (F and G) Quantification of tube formation (F) and chemotaxis assay using 
Boyden chambers (G) of HUVECs incubated with microparticles isolated from MCS-fed mice 
(control diet) and MCD-fed mice treated with VNN1 siRNA, control siRNA, or PBS (mock) (n = 5 
mice per group). VEGF was used as a positive control, and serum-free medium as a negative 
control. Values in (C), (E), (F), and (G) represent means ± SD from three independent experiments. 
*P < 0.05; **P < 0.01; ***P < 0.001, Kruskal-Wallis with Bonferroni correction. 
We also placed caspase 3 knockout (Casp3
−/−
) mice on the MCD or MCS diet. Histological 
examination showed that both Casp3
−/−
 and wild-type mice on the MCD diet developed 
predominantly macrovesicular steatosis and lobular inflammation (fig. S15A), although the extent 
of pathological angiogenesis in Casp3
−/−
 mice (fig. S15, A, B, and D) on the MCD diet was reduced 
(fig. S15, A, C, and D). Collectively, these findings identify hepatocyte-derived microparticles as a 
potential link between lipotoxicity and angiogenesis, with a crucial involvement of caspase 3 in this 
process. 
Discussion 
This study demonstrates that overloading hepatocytes with saturated lipotoxic FFAs results in the 
release of proangiogenic hepatocyte-derived microparticles in a process that requires caspase 3 
activation. Proteomic analysis identified VNN1, an epithelial ectoenzyme involved in cell adhesion 
and migration, as an abundant surface protein in hepatocyte-derived microparticles, and functional 
studies demonstrate that the proangiogenic effects of microparticles require internalization by 
endothelial cells in a process dependent on VNN1 and lipid rafts. Angiogenesis plays a central role 
in chronic liver disease (7) and may be involved in the progression from hepatic steatosis, a 
generally benign condition characterized by overaccumulation of lipids in the liver, to NASH, 
which is a potentially more severe condition associated with lipid overloading of the liver, 
inflammation, and variable degrees of fibrosis. Indeed, marked hepatic neovascularization has been 
reported both in patients with NASH and in experimental models of the disease and correlates with 
the extent of detectable fibrosis (8–11, 43). The pathogenic mechanisms resulting in angiogenesis in 
NASH remain poorly understood, although increased production and release of certain 
proangiogenic factors such as VEGF-A, likely as a result of local hypoxia due to enlarged 
hepatocytes (which are swollen with accumulated lipids) or VEGF receptor 2 signaling, have been 
implicated (7, 44). We hypothesized that lipid-overloaded hepatocytes may release proangiogenic 
signals that regulate endothelial cell migration and angiogenesis. Here, we showed that lipotoxicity 
induced by incubation of hepatocytes with saturated FFAs such as palmitic acid results in the 
release of factors that induce endothelial cell migration and vascular tube formation. Although the 
contribution of inflammatory cells in angiogenesis during chronic liver damage has been 
characterized (45, 46), less is known about the potential contribution of hepatocytes to this process. 
We identified hepatocyte-derived microparticles as a link between hepatocyte lipotoxicity and 
angiogenesis. Circulating microparticles are increased in animal models of biliary cirrhosis and 
human cirrhosis and NASH (47–49). Microparticles are small membrane-bound particles or 
microvesicles released from the surface membrane of many cell types spontaneously or upon 
stimulation by various stressors (50, 51) and can participate in cell-to-cell communication (45, 50). 
Microparticle function depends on the cell type from which they originate and their content. Our 
analysis of the composition of hepatocyte-derived microparticles using proteomic approaches 
identified various proteins that appear to be specific for hepatocyte-derived microparticles (52–54), 
as well as proteins that are present in microparticles of other cell origins and in exosomes secreted 
by hepatocytes (43, 46, 52, 55). Future studies to compare the protein composition of hepatocyte-
derived microparticles with those of microparticles from other cell types, as well as from exosomes 
secreted by hepatocytes, are warranted. 
We demonstrated that a large number of microparticles were present in the liver and in circulation 
of mice fed the MCD diet, a common animal model of NASH (56), and that a substantial number of 
these circulating microparticles originated from hepatocytes. Furthermore, VNN1 was abundant on 
microparticles from mice on the MCD diet, and these microparticles promoted tube formation and 
migration of endothelial cells in vitro. siRNA-mediated targeting of VNN1 in mice on the MCD 
diet reduced the proangiogenic effects of the microparticles isolated from these mice but not their 
amount in the bloodstream. Moreover, MCD-fed animals showed increased pathological 
angiogenesis in the liver, which was reduced in VNN1 siRNA–treated animals. The localization of 
microparticles in the space of Disse, the location in the liver between hepatocytes and a sinusoid, 
suggests that these microparticles act in a paracrine manner. However, because the number of 
circulating VNN1-positive microparticles increased in the mouse model of NASH, we cannot rule 
out the possibility that microparticles released into the circulation act as long-range signals that may 
also contribute to pathological angiogenesis in the liver. The precise molecular mechanisms of 
microparticle release in hepatic angiogenesis and liver damage will require further investigation. 
Moreover, future studies are necessary to further dissect VNN1-mediated internalization and a 
potential role for its enzymatic function during the fusion of microparticles with lipid raft domains, 
as well as the role of other proteins, lipids, and RNA species including microRNAs (miRNAs) in 
microparticles that could have additional or synergistic effects to those induced by VNN1. In 
summary, our data support a model in which hepatocytes exposed to saturated lipotoxic FFAs such 
as palmitic acid release microparticles in a process requiring caspase 3 activation, which, in turn, 
can initiate endothelial cell migration and induce angiogenesis through VNN1-mediated 
microparticle internalization. Together, our results identify hepatocyte-derived VNN1-positive 
microparticles as an attractive potential target for developing novel antiangiogenic therapeutic 
strategies for the treatment of NASH as well as a circulating biomarker of liver damage. 
Materials and Methods 
Animal studies 
C57BL/6 caspase 3 knockout (Casp3
−/−
) mice were provided by M. Woo (University of Toronto). 
These mice were generated by deleting exon 3 of the CPP32/caspase 3 gene as previously described 
(57). Casp3
−/−
 and wild-type littermates (7 weeks old, 20 to 25 g in body weight) were placed on an 
MCD diet (MP Biomedicals). An MCS diet (MP Biomedicals) and chow diet were used as control 
diets. A Western diet with HF/HCarb content has been used as a model of diet-induced NAFLD. 
Total body weight was measured weekly in all mice. Mice were sacrificed after 6 weeks on their 
respective diets, and livers and blood were collected under deep anesthesia as previously detailed 
(34). Athymic BALB/c nude mice (Case Western Reserve University athymic nude mice facility, 
Cleveland, OH; 6 weeks old, 20 to 25 g in body weight) were used for the in vivo Matrigel 
migration and angiogenesis assay. All animals were treated in compliance with the Guide for the 
Care and Use of Laboratory Animals (National Academy of Science, Washington, DC), and animal 
procedures were approved by the University of California, San Diego, Institutional Animal Care 
and Use Committee. 
Histopathology and immunohistochemistry 
Liver tissue was fixed in 10% formalin and paraffin-embedded. Tissue sections (5 μm) were 
prepared and stained with hematoxylin and eosin to assess histological changes including the degree 
of steatosis, ballooning of hepatocytes, and inflammation under light microscopy. The presence of 
endothelial cells was assessed by immunostaining with polyclonal rabbit antibody against CD31 
(1:25; Abcam) and polyclonal rabbit antibody against von Willebrand factor (1:300; Dako). 
Deparaffinized sections were immersed in 3% H2O2 in water for 15 min to eliminate endogenous 
peroxidase activity. Sections were processed for heat-induced epitope retrieval for 20 min with 
Dako Target Retrieval Solution (pH 6.0; Dako) and stained overnight at 4°C. After incubation with 
secondary antibody, immune complexes were detected with the Dako EnVision System with HRP 
according to the manufacturer’s instructions. Quantification of CD31 staining was performed with 
customized histology quantification software provided by Wimasis, and the percentage of CD31 
staining is reported. 
Cell culture 
Primary rat hepatocytes were purchased from Becton Dickinson (BD) and maintained in Hepato-
STIM Hepatocyte Defined Medium (BD) supplemented with 5 μg of epidermal growth factor and 2 
mM l-glutamine. The human hepatoma HepG2 cell line was maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum 
(CellGro), penicillin (5000 U/ml), and streptomycin sulfate (5000 μg/ml) in 0.85% NaCl. HUVECs 
were maintained in EGM-2 growth medium (Lonza) supplemented with several angiogenic and 
growth factors (SingleQuots, Lonza) according to the manufacturer’s instructions. Cells were 
cultured at 37°C in a 5% CO2 humidified environment and used between passages 2 and 6. During 
treatments, HUVECs were incubated with growth factor–free medium (EBM-2, Lonza). Palmitic, 
stearic, oleic, and linoleic acids (Sigma-Aldrich) were dissolved in 95% ethanol (100 mM stock 
solution) and stored at −20°C before the experiments. 
Microparticle isolation and purification 
For microparticle isolation, HepG2 and primary rat hepatocytes were seeded onto a 100-mm dish 
and cultured until they reached 80 to 85% confluency. Cells were incubated with 0.25 mM palmitic, 
stearic, oleic, or linoleic acid in serum-free DMEM, supplemented with 1.1% penicillin and 
streptomycin and 1% endotoxin-free BSA, for up to 24 hours. The amount of FFAs used was 
physiologically relevant and was comparable to that detected in obese patients (15). The uptake of 
FFAs from hepatocytes was evaluated with an Oil Red-O staining kit (Cayman) according to the 
manufacturer’s instruction. To determine the effect of caspase 3 activity, we treated hepatocytes 
with the caspase 3 inhibitor Ac-DEVD-CHO (BD Pharmingen). Control cells were incubated with 
the same serum-free medium supplemented with the vehicle used to dissolve the FFAs. After 24 
hours, the medium was collected and centrifuged twice at 3000 rpm for 15 min to remove cell 
debris and aggregates. Supernatants were then transferred to new tubes and ultracentrifuged at 
100,000g for 90 min at 10°C to avoid contamination of exosomes (58). Supernatants were collected 
in new tubes and used as a microparticle-free control, and the pelleted microparticles were 
resuspended in 200 μl of PBS for flow cytometry or in 500 μl of EGM-2 growth medium for 
subsequent in vitro studies. The concentration of microparticles was determined by the 
bicinchoninic acid (BCA) protein assay, and different concentrations of microparticles (50, 125, 
250, and 500 μg/ml) were used to perform dose-dependent angiogenesis in vitro assays. For 
selected purposes, in particular for the characterization analyses, crude microparticles were purified 
by 10 to 70% sucrose gradient ultracentrifugation at 150,000g for 18 hours at 10°C and collected as 
fractions in new tubes. Fractions were resolved by SDS–polyacrylamide gel electrophoresis precast 
gels (Bio-Rad) and then visualized by silver staining (Invitrogen) to detect proteins in each fraction. 
Fractions with a density between 1.17 and 1.25 mg/ml and corresponding to the microparticles were 
combined, resuspended in PBS, and ultracentrifuged at 100,000g for 1 hour at 10°C to remove 
sucrose. For the isolation of microparticles from Casp3
−/−
 and wild-type mice, blood was collected 
by cardiac puncture into BD vacutainer tubes containing 100 μl of acid citrate dextrose (0.085 M 
sodium citrate, 0.0702 M citric acid, 0.111 M dextrose, pH 4.5) as anticoagulant (Medcompare). 
Whole blood was centrifuged for 15 min at 200g at room temperature to obtain the platelet-rich 
plasma (supernatant). Platelet-rich plasma was centrifuged again for 2 min at 13,000g at room 
temperature to remove contaminating platelets and obtain platelet-free plasma. Microparticles were 
incubated in the dark for 30 min at room temperature with or without 5 μl of Alexa Fluor 488–
conjugated annexin V (Molecular Probe). The microparticle diameter was assessed by dynamic 
light scattering (Zetasizer, Malvern). 
Flow cytometry 
Flow cytometry analyses for microparticle or endothelial cell detection were performed with the BD 
LSRII flow cytometer system (BD Biosciences), and data were analyzed with FlowJo software 
(TreeStar Inc.). For microparticle analysis, a standardization was achieved with 1-μm latex 
fluorescent beads (Sigma-Aldrich) and ultraviolet 2.5-μm flow cytometry alignment beads 
(Invitrogen). Forward scatter and side scatter limits were plotted on logarithmic scales to cover a 
wide size range. Single staining controls were used to check fluorescence compensation settings and 
to set up positive regions. For endothelial cell analysis, cells were incubated with labeled 
microparticles for 16 hours, trypsinized, and resuspended in fresh medium. 
Tube formation 
HUVECs (0.5 × 10
5
 to 1 × 10
5
 cells per well) were seeded onto a coated 24-well plate with Matrigel 
(200 μl/cm2; BD) using the thick gel method and cultured in EBM-2 basal medium supplemented 
with 1.1% of streptomycin and penicillin in the presence of VEGF (100 ng/ml; PeproTech), 
hepatocyte-derived microparticles, microparticle-free supernatant, or conditioned supernatant 
collected after 24 hours of treatment with FFAs. In some studies, the RhoA-ROCK inhibitor 
Y27632 (10 μM) was used in association with microparticles in the treatment of endothelial cells. 
For the ex vivo studies, platelet-free plasma isolated from different groups of mice (chow-, 
HF/HCarb-, and MCD-fed mice and mice injected with control RNA, VNN1 siRNA, or PBS as 
vehicle) was ultracentrifuged at 100,000g for 1 hour at 10°C to pellet the blood microparticles. 
HUVECs were treated with microparticles (or microparticles purified from blood) and incubated for 
5 hours at 37°C. Tube formation was investigated by capturing images on an inverted microscope at 
×4 magnification. Tube formation image analysis was assessed with Wimtube software (Wimasis), 
and the values of total tube length (pixel) were used for statistical and data analysis. 
Cell migration 
In vitro migration studies were performed with HUVECs. Wound healing assays were performed to 
analyze chemokinesis (nonoriented migration) with a collagen-coated six-well culture plate, in 
which a silicon elastomer (polydimethylsiloxane) strip was placed vertically at the bottom of every 
well to create an artificial wound. HUVECs were plated and grown until they reached complete 
confluence. HUVECs were treated with EBM-2 supplemented with VEGF (100 ng/ml; PeproTech), 
hepatocyte-derived microparticles, microparticle-free supernatant, or supernatant collected after 24 
hours of treatment with FFAs. The strips were removed carefully, and migration of cells was 
detected by a confocal microscope, capturing one image per field every 10 min for 48 hours. 
Mitomycin (1 μg/ml) was used to inhibit cell proliferation during wound healing assays. Data were 
analyzed with WimScratch software (Wimasis) to obtain the total cell-covered area (pixel). Boyden 
chamber assays were performed to analyze chemotaxis (oriented migration) by using cell culture 
inserts with 8-μm pore size (Millipore) and a 24-well plate. Each well was filled with 500 μl of 
serum-free EBM-2 medium in the presence or absence of the following chemoattractants: VEGF 
(100 ng/ml), hepatocyte-derived microparticles, and microparticle-free supernatant or conditioned 
supernatant. The inserts were placed on top of each well, and 150 μl of cell suspension (5 × 104 
cells) was added. Plates were incubated overnight at 37°C, and then the filters were removed and 
stained with Vectashield mounting medium with DAPI (Vector Labs). Migrated cells were detected 
with a fluorescence microscope, and the number of nuclei per field was counted. For the ex vivo 
studies, platelet-free plasma isolated from different groups of mice (chow-, HF/HCarb-, MCD-fed 
mice and mice injected with control siRNA, VNN1 siRNA, or PBS as vehicle) was ultracentrifuged 
at 100,000g for 1 hour at 10°C to pellet the blood microparticles. 
In vivo Matrigel migration and angiogenesis assay 
To determine the ability of hepatocyte-derived microparticles to induce angiogenesis, athymic 
BALB/c nude mice were subcutaneously injected with 0.5 to 1 ml of ice-cold Matrigel Matrix 
Growth Factors Reduced (BD), mixed with VEGF (100 ng/ml), hepatocyte-derived microparticles, 
or microparticle-free supernatant. A volume of Matrigel only was used as a negative control. After 
14 days, Matrigel plugs were removed along with surrounding tissue for orientation, fixed in 10% 
formalin, and embedded in paraffin. Sections (5 μm) were successively stained for Masson’s 
trichrome to detect endothelial cells (in dark red). The number of endothelial cells that migrated into 
the plug after the treatment was counted. The number of endothelial cells that migrated is reported 
in the graph as number per field. 
Proliferation assay 
Fat-laden HepG2-derived microparticles were treated with neutralizing rabbit antibody against 
VNN1 (4 μg/ml; Epitomics) for 30 min. Serum-starved HUVECs were treated with hepatocyte-
derived microparticles, microparticle-free supernatant, VNN1-neutralized microparticles, VEGF 
(100 ng/ml), and negative control for up to 16 hours. Cells were then treated with the 5-bromo-2′-
deoxyuridine (BrdU) for up to 4 hours. After the labeling medium was removed, cells were 
resuspended in anti-BrdU antibody (1:8, BD) for 30 min at room temperature. Goat anti-mouse 
immunoglobulin G–Alexa Fluor 488 (1:500; Life Technologies) was added, and cells were 
incubated for 30 min at room temperature. Cells were counterstained with propidium iodide. FITC-
positive cells were detected by the BD LSRII flow cytometer system and quantified as described 
previously (59). 
In vitro and in vivo siRNA-mediated knockdowns 
HepG2 cells were trypsinized, and 8 × 10
5
 cells were seeded in a six-well plate. To knock down 
VNN1 or PPARα in hepatocytes, HepG2 cells were incubated with 50 nM siRNA for VNN1 or 
PPARα and control siRNA dissolved in Lipofectamine 2000 (Life Technologies). Transfection was 
performed according to the manufacturer’s instructions. Forty-eight hours after transfection, cells 
were treated with 0.25 mM palmitic acid for 24 hours, and microparticles were isolated from the 
supernatant by ultracentrifugation. Additionally, a flow cytometric analysis of hepatocyte-derived 
microparticles was performed with a phycoerythrin-conjugated VNN1 antibody (Santa Cruz 
Biotechnology) to test the efficiency of the transfection. To knock down cdc42, HUVECs were 
trypsinized, seeded in a six-well plate, and incubated with 50 nM cdc42 siRNA and control siRNA 
dissolved in Lipofectamine 2000 (Life Technologies). Transfection was performed according to the 
manufacturer’s protocol. Forty-eight hours after transfection, cells were used for chemotaxis and 
tube formation assays. In vivo VNN1 knockdown during experimental NASH was performed by 
injecting VNN1 Stealth RNA (Life Technologies), control siRNA, or PBS as vehicle (mock) on a 
weekly basis into C57BL/6 mice fed with the MCD diet for 6 weeks. To deliver siRNA, we used 
Invivofectamine Rx (Life Technologies) according to the manufacturer’s instructions. For the 
siRNA injection, the following approach was used: week 1, 3, and 5 mice received siRNA–
Invivofectamine Rx (1.5 mg/kg) or control siRNA, whereas week 2, 4, and 6 mice received siRNA–
Invivofectamine Rx (0.75 mg/kg) or control siRNA. As previously described, the siRNA injection 
in vivo does not cause any major pathological consequences in the liver or side effects in mice (60). 
Internalization of microparticles into endothelial cells 
To investigate microparticle internalization into HUVECs by flow cytometry, microparticles were 
stained with 1 μM calcein AM (MPcalcein) (BD Biosciences), a fluorescent dye with an emission 
wavelength of 515 nm, for 1 hour in the dark at 37°C. Microparticles were centrifuged twice with 
PBS for 30 min at 35,000 rpm and resuspended in 500 μl of EGM-2 medium. To block 
microparticle internalization, MP
calcein
 were incubated with or without rabbit polyclonal VNN1 
antibody (4 μg/ml) (S3055; Epitomics) for 30 min at room temperature. A rabbit glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (Abcam) was used as a control. After the incubation, 
microparticles were incubated with serum-starved HUVECs seeded in a 24-well plate (15 × 10
4
 
cells per well) for 6 hours at 37°C. Cells were trypsinized, and FITC-positive HUVECs were 
detected with the BD LSRII flow cytometer system (BD) and counted. For the immunofluorescence 
studies, HUVECs were seeded in four-chamber culture slides (BD Biosciences) and serum-starved 
for 4 hours. Microparticles were isolated from the supernatant of HepG2 cells treated with palmitic 
acid, resuspended in 1 ml of Diluent C (G8278, Sigma-Aldrich), and gently pipetted to ensure 
complete dispersion. The 1-ml microparticle suspension was added to 1 ml of Diluent C with 4 μl of 
PKH26 solution (MP
PKH26
), a lipophilic dye that stably integrates into the cell membrane (MINI26, 
Sigma-Aldrich). The microparticle suspension was incubated in the dark for 4 min, and then 2 ml of 
1% BSA was added and kept for 1 min to stop the reaction. The microparticle suspension was 
ultracentrifuged for 30 min at 35,000 rpm, and the pellet was resuspended in 200 μl of HUVEC 
medium. HUVECs seeded in the culture slide were incubated with MP
PKH26
 for 1 and 6 hours at 
37°C in the dark. After incubation, medium was removed from each well, and HUVECs were 
washed twice with PBS and fixed with 4% paraformaldehyde solution in PBS for 10 min at room 
temperature. HUVECs were then stained with 5 μl of Alexa Fluor 488–phalloidin (Invitrogen) in 
200 μl of PBS according to the manufacturer’s instructions. After being washed three times with 
PBS, HUVECs were stained with DAPI (Vector Labs). Slides were imaged with an Olympus 
FV1000 spectral confocal microscope. The role of lipid rafts in the internalization of microparticles 
into HUVECs was investigated by cholesterol depletion and inhibition of the lipid raft–associated 
protein caveolin-1. HUVECs (4 × 10
3
 cells per well) were seeded onto a 24-well plate, and 
depletion of cholesterol was assessed by treatment with 10 mM MβCD in serum-free EBM-2 
medium for 15 min at 37°C, followed by washing with fresh medium. To inhibit caveolin-1, 
HUVECs seeded in a 24-well plate were treated with rabbit anti-human caveolin-1 neutralizing 
antibody (2.5 μg/ml) (Sigma Aldrich) in serum-free EBM-2 medium containing 0.01% Triton X-
100 for 30 min at 37°C, as previously described (27). Cholesterol-depleted or caveolin-1 
neutralizing antibody–treated HUVECs were incubated for 6 hours with MPPKH26 to assess the 
internalization by immunofluorescence. The interaction between VNN1 on the microparticle 
surface and lipid rafts on HUVECs was assessed by electron microscopy, as previously reported 
(61). After washing, 1 to 2 ml of cold 4% paraformaldehyde in 0.1 M phosphate buffer were 
pipetted onto the HUVECs, which were then gently lifted off tissue culture plates with cell lifters. 
After a short low-speed spin, the fixative was removed from the pellet, and fresh fixative was added 
to resuspend the cells. The cells were then fixed at 4°C for 1 hour and washed extensively. After 
blocking for 30 min with 1% BSA in PBS, cells were incubated overnight at 4°C with rabbit anti-
human polyclonal antibody against VNN1 (Epitomics) with gentle rotation. After washing, 15-nm 
protein A–gold conjugate (1:25 in 1% BSA) (Ted Pella) was bound to VNN1 for 2 hours at room 
temperature, with gentle rotation. The cells were washed carefully, and HRP was reacted with 3,3′-
diaminobenzidine (DAB;10 mg/ml) in PBS for 5 min and then with DAB in PBS with 0.0003% 
H2O2 for 30 min in the dark. After being washed, cells were refixed with 1% glutaraldehyde and 
processed for routine electron microscopy. After standard ethanol dehydration, pellets were 
embedded in LX112 medium (Ladd) and polymerized for 48 hours at 60°C. Blocks were sectioned 
at 70 nm, and grids were viewed unstained to enhance HRP-DAB reaction. 
Electron and confocal microscopy 
For TEM, microparticles were adhered to 100-mesh Formvar- and carbon-coated grids for 5 min at 
room temperature. Grids were washed once with water, stained with 1% uranyl acetate (Ladd 
Research Industries) for 1 min, dried, and viewed with a JEOL 1200 EXII TEM. Images were 
captured with a Gatan Orius 600 digital camera (Gatan). Liver samples were collected from mice on 
the MCD diet after a short liver perfusion with 10 ml of 4% paraformaldehyde in 0.15 M sodium 
cacodylate buffer (pH 7.4) with a 21-gauge needle. Samples were immersed in modified 
Karnovsky’s fixative [2.5% glutaraldehyde and 2% paraformaldehyde in 0.15 M sodium cacodylate 
buffer (pH 7.4)] for at least 4 hours, postfixed in 1% osmium tetroxide in 0.15 M cacodylate buffer 
for 1 hour, and stained en bloc in 3% uranyl acetate for 1 hour. Samples were dehydrated in ethanol, 
embedded in Durcupan epoxy resin (Sigma-Aldrich), sectioned at 50 to 60 nm on a Leica UCT 
ultramicrotome, and picked up on Formvar- and carbon-coated copper grids. Sections were stained 
with 3% uranyl acetate for 5 min and Sato’s lead stain for 1 min. Grids were viewed with a JEOL 
1200 EX II TEM and photographed with a Gatan digital camera (Gatan). Images of microparticles 
internalized by HUVECs were captured by an Olympus FV1000 spectral confocal microscope with 
40× lens and Alexa Fluor 488 and Texas Red filters. Analysis of images was performed with 
ImageJ software (version 1.4.3.67). For the immunogold electron microscopy related to the 
internalization of VNN1-positive microparticles through the lipid raft, see “Internalization of 
microparticles into endothelial cells.” 
RNA isolation, real-time polymerase chain reaction, and miRNA analysis 
Tissue (liver, intestine, spleen, or kidney) from MCD- and MCS-fed mice (Casp3
−/−
, wild type, 
treated with VNN1 siRNA or controls) was homogenized with the FastPrep 24 bead 
homogenization system. HUVECs or HepG2 cells were trypsinized, resuspended in lysis buffer, 
and homogenized by mechanical fraction with a 1-ml syringe. Total RNA was isolated with RNeasy 
kit (Qiagen) and reverse-transcribed with iScript cDNA Synthesis Kit (Bio-Rad) according to the 
manufacturer’s instructions. The concentration and purity of RNA were assessed by NanoDrop 
(Thermo Scientific). Quantitative real-time polymerase chain reaction (PCR) was performed on a 
Bio-Rad Cycler (Bio-Rad) with the SYBR Green Real-Time PCR Master Mix (Kapa Biosystems) 
according to the manufacturer’s instructions. The housekeeping gene 18S was used as an internal 
control. The PCR primers used to amplify each gene were as follows: VEGF-A, 5′-
GCACATAGAGAGAATGAGCTTCC-3′ (forward) and 5′-CTCCGCTCTGAACAAGGCT-3′ 
(reverse); FGF-β, 5′-TTGTGTCTATCAAGGGAGTGTGT-3′ (forward) and 5′-
TGCCACATACCAACTGGAGTATT-3′ (reverse); VE-cadherin, 5′-
CACTGCTTTGGGAGCCTTC-3′ (forward) and 5′-GGGGCAGCGATTCATTTTTCT-3′ (reverse); 
PPARγ, 5′-TACTGTCGGTTTCAGAAATGCC-3′ (forward) and 5′-
GTCAGCGGACTCTGGATTCAG-3′ (reverse); PPARα, 5′-TTCGCAATCCATCGGCGAG-3′ 
(forward) and 5′-CCACAGGATAAGTCACCGAGG-3′ (reverse); murine VNN1, 5′-
CTTTCCTCGCGGCTGTTTAC-3′ (forward) and 5′-CCTCCAGGTATGGGTAGATCGT-3′ 
(reverse); human VNN1, 5′-ACGTGGACACCATAGTATTCCC-3′ (forward) and 5′-
ATGCAAGGAAATTGACCCTCAT-3′ (reverse). For isolation and quantification of miR-122, 
platelet-free plasma isolated from MCD-fed mice was incubated with ribonuclease (10 μg/ml; 
Roche) for 30 min at 37°C to remove any RNAs adhering to the external leaflet of circulating 
microparticles. Circulating microparticles were then ultracentrifuged at 100,000g for 90 min at 
10°C. Total encapsulated RNAs in microparticles, including miRNAs, were isolated with 
miRNeasy Mini Kit (Qiagen). Complementary DNA (cDNA) was synthesized using specific 
miRNA primers (Applied Biosystems) with TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems). miRNA abundance was detected with TaqMan probe (Applied Biosystems) 
on a 7300 Real-Time PCR System (Applied Biosystems). The U6 snRNA was used as an internal 
control and to normalize miR-122 expression. 
Sample preparation for MS 
Protein samples were diluted in TNE buffer [50 mM tris (pH 8.0), 100 mM NaCl, 1 mM EDTA]. 
RapiGest SF reagent (Waters Corp.) was added to a final concentration of 0.1%, and samples were 
boiled for 5 min. TCEP [tris(2-carboxyethyl)phosphine] was added to a final concentration of 1 
mM, and the samples were incubated at 37°C for 30 min. Subsequently, the samples were 
carboxymethylated with iodoacetamide (0.5 mg/ml) for 30 min at 37°C, followed by neutralization 
with 2 mM TCEP (final concentration). Protein samples prepared as above were digested with 
trypsin (trypsin/protein ratio, 1:50) overnight at 37°C. RapiGest was degraded and removed by 
treating the samples with 250 mM HCl at 37°C for 1 hour, followed by centrifugation at 14,000 rpm 
for 30 min at 4°C. The soluble fraction was then added to a new tube, and the peptides were 
extracted and desalted with Aspire RP30 desalting columns (Thermo Scientific) (62). 
LC-MS/MS analysis 
Trypsin-digested peptides were analyzed by high-performance liquid chromatography (HPLC) 
coupled with tandem mass spectroscopy (LC-MS/MS) using nanospray ionization (63). The 
nanospray ionization experiments were performed with a TripleTOF 5600 hybrid mass 
spectrometer (AB Sciex) interfaced with nanoscale reversed-phase HPLC (Tempo) with a glass 
capillary (10-cm length × 100-μm inner diameter) packed with 5-μm C18 Zorbax beads (Agilent 
Technologies). Peptides were eluted from the C18 column into the mass spectrometer with a linear 
gradient (5 to 60%) of acetonitrile (ACN) at a flow rate of 250 μl/min for 1 hour. The buffers used 
to create the ACN gradient were as follows: buffer A [98% H2O, 2% ACN, 0.2% formic acid, and 
0.005% trifluoroacetic acid (TFA)] and buffer B (100% ACN, 0.2% formic acid, and 0.005% TFA). 
MS/MS data were acquired in a data-dependent manner in which the MS1 data were acquired for 
250 ms at mass/charge ratios (m/z) of 400 to 1250 daltons, and the MS/MS data were acquired from 
m/z of 50 to 2000 daltons. The independent data acquisition criteria included 50 MS2 scans from 
the survey MS1 scan where the parent ion signal intensity was above 200 counts threshold and the 
charge state of parent ion was +2 to +4 ions and the exclusion time was set to 4 s. Finally, the 
collected data were analyzed with Mascot (Matrix Sciences) and ProteinPilot 4.0 (AB Sciex) for 
peptide identification. 
Protein analysis 
HepG2 were treated with 1% BSA and 0.25 mM palmitic acid or oleic acid for 24 hours. Whole-
cell lysates were digested in 400 μl of radioimmunoprecipitation assay buffer containing Protease 
Inhibitor Cocktail tablets (Roche). Microparticles were isolated from the same cells or from animal 
blood and resuspended in lysis buffer. Proteins were measured with the Pierce BCA Protein Assay 
Kit (Thermo Scientific). About 10 μg of protein for microparticles and 30 to 40 μg of protein for 
HepG2 cells were resolved by 4 to 20% tris-HCl gel electrophoresis (Bio-Rad) and transferred onto 
polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked for 1 hour at room 
temperature with 3 to 5% low-fat milk (Bio-Rad) in 1× PBS, 0.1% Tween 20 (PBS-T). Primary 
rabbit anti-human polyclonal antibody against VNN1 (Epitomics), anti-mouse VNN1 (Proteintech), 
antibody against vascular cell adhesion molecule–1 (Santa Cruz Biotechnology), mouse monoclonal 
antibody against intercellular adhesion molecule–1 (Abnova), and anti-GAPDH (Cell Signaling) 
were incubated overnight at 4°C. After being washed with PBS-T, the membranes were incubated 
with goat anti-rabbit or mouse secondary antibody, and proteins were visualized with SuperSignal 
West Pico chemiluminescence substrate (Pierce Biotechnology). Densitometry analysis of the 
specific protein bands was performed with ImageJ (version 1.4.3.67). 
Statistical analysis 
Data are presented as means ± SD unless otherwise indicated. Differences between three or more 
groups were compared by ANOVA. If data deviated from the normal distribution, a nonparametric 
Kruskal-Wallis test was performed. If a significant effect was detected, post hoc pairwise 
comparisons were performed with Bonferroni correction. Differences between two groups of data 
with a nonnormal distribution were compared by the Mann-Whitney test. The Kolmogorov-
Smirnov test was used to determine the normal distribution of data. Differences were considered to 
be statistically significant at P < 0.05. Statistical analysis was performed with GraphPad Prism 4.0c. 
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Fig. S1. HepG2 exposed to different saturated and unsaturated FFAs. 
Fig. S2. The effect of lipotoxic FFAs is counteracted by nonlipotoxic FFAs. 
Fig. S3. Cellular localization and molecular function of proteins from hepatocyte-derived 
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angiogenesis. 
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Fig. S6. Hepatocyte-derived microparticles are detectable in HUVEC tube structures. 
Fig. S7. Depletion of VNN1 reduces the ability of microparticles to promote HUVEC migration and 
tube formation. 
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internalization. 
Fig. S9. The proangiogenic effects of VNN1-positive microparticles are not mediated by induction 
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of PPARα or PPARγ. 
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vitro. 
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 mice show reduced MCD-induced pathological angiogenesis. 
Table S1. Identification of proteins in hepatocyte-derived microparticles on the basis of the LC-
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